MCID: DDN006
MIFTS: 50

Duodenitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Duodenitis

MalaCards integrated aliases for Duodenitis:

Name: Duodenitis 12 54 44 15 71 32
Hemorrhagic Duodenitis 12 71
Acute Enteritis of the Mouse Intestinal Tract 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8643
ICD9CM 34 535.6
MeSH 44 D004382
NCIt 50 C94409
SNOMED-CT 67 155715004
ICD10 32 K29.8
UMLS 71 C0013298 C0341245 C1522057

Summaries for Duodenitis

MalaCards based summary : Duodenitis, also known as hemorrhagic duodenitis, is related to gastrointestinal ulceration, recurrent, with dysfunctional platelets and gastritis. An important gene associated with Duodenitis is GAST (Gastrin), and among its related pathways/superpathways are T cell receptor signaling pathway and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Amoxicillin and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, liver and bone, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Wikipedia : 74 Duodenitis is inflammation of the duodenum. It may persist acutely or... more...

Related Diseases for Duodenitis

Diseases related to Duodenitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 661)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal ulceration, recurrent, with dysfunctional platelets 31.1 S100A8 GAST
2 gastritis 30.9 TNF S100A8 GAST ATP4A
3 duodenal ulcer 30.3 TNF S100A8 INS GAST CCK
4 eosinophilic gastritis 30.2 ATP4A ATP12A
5 cholecystitis 30.2 S100A8 CCK ALB
6 atrophic gastritis 30.2 TNF S100A8 GAST
7 gastric ulcer 30.2 TNF S100A8 GAST
8 granulomatous gastritis 30.1 GAST ATP4A ATP12A
9 active peptic ulcer disease 30.1 ATP4A ATP12A ALB
10 peptic ulcer disease 30.1 TNF S100A8 GAST ATP4A ATP12A
11 gastroduodenitis 30.1 GAST CD8A CD4 ATP4A ATP12A
12 gastritis, familial giant hypertrophic 30.0 GAST ATP4A ATP12A ALB
13 duodenogastric reflux 29.8 GAST CCK ATP4A ATP12A
14 superior mesenteric artery syndrome 29.7 CRP ATP4A ATP12A
15 esophageal varix 29.6 INS ATP4A ATP12A ALB
16 pancreatitis 29.5 TNF INS CRP CCK
17 hyperthyroidism 29.5 INS CRP ALB
18 crohn's disease 29.4 TNF S100A8 CRP CD4 ALB
19 peritonitis 29.4 TNF CRP ALB
20 esophageal candidiasis 29.3 CD8A CD4 ATP4A ATP12A
21 mononeuritis multiplex 29.2 TNF CRP CD4
22 gallbladder disease 29.2 INS CRP CCK ALB
23 ileus 29.2 TNF INS CRP CCK
24 peptic ulcer perforation 29.2 S100A8 CRP ATP4A ATP12A ALB
25 obstructive jaundice 29.2 TNF CRP ALB
26 endocarditis 29.1 TNF CRP ALB
27 acute pancreatitis 29.1 TNF INS CRP CCK
28 gastroenteritis 29.1 TNF CRP ALB
29 gastroesophageal reflux 29.1 TNF S100A8 GAST CCK
30 irritable bowel syndrome 29.1 TNF TGM2 CRP CCK
31 aortic aneurysm, familial abdominal, 1 29.1 TNF CRP ALB
32 visceral leishmaniasis 29.1 TNF CRP ALB
33 peptic esophagitis 29.1 TNF S100A8 GAST ATP4A ATP12A ALB
34 diarrhea 29.1 TNF TGM2 GAST CCK ALB
35 cholelithiasis 29.0 INS GAST CRP CCK ALB
36 giardiasis 29.0 TOR1A TGM2 CD8A CD4 ATP4A ATP12A
37 end stage renal disease 28.9 TNF INS CRP ALB
38 sarcoidosis 1 28.9 TNF CRP CD8A CD4
39 liver cirrhosis 28.9 TNF INS CRP ALB
40 intestinal tuberculosis 28.9 TNF CRP CD4 ALB
41 intestinal obstruction 28.9 CRP CD8A ATP4A ATP12A ALB
42 acquired immunodeficiency syndrome 28.8 TNF CRP CD4 ALB
43 biliary tract disease 28.8 TNF CRP CD4 CCK ALB
44 constipation 28.8 INS GAST CRP CCK ATP4A ATP12A
45 panniculitis 28.7 TNF CRP CD8A CD4
46 myeloma, multiple 28.6 TNF CD8A CD4 ALB
47 lymphocytic colitis 28.4 TOR1A TNF TGM2 CD8A ATP4A ATP12A
48 dysentery 28.4 TNF CRP CD4 ATP4A ATP12A ALB
49 deficiency anemia 28.2 TOR1A TNF INS CRP ATP4A ATP12A
50 pancreatic cancer 28.0 TNF TGM2 INS GAST CD4 CCK

Comorbidity relations with Duodenitis via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Atrophic Gastritis
Bronchitis Deficiency Anemia
Esophageal Disease Esophagitis
Heart Disease Hypertension, Essential
Intermediate Coronary Syndrome Iron Deficiency Anemia
Paralytic Ileus

Graphical network of the top 20 diseases related to Duodenitis:



Diseases related to Duodenitis

Symptoms & Phenotypes for Duodenitis

MGI Mouse Phenotypes related to Duodenitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.91 ALB ATP4A CCK CD4 CD8A GAST
2 homeostasis/metabolism MP:0005376 9.9 ALB ATP12A ATP4A CCK CD4 CRP
3 digestive/alimentary MP:0005381 9.87 ALB ATP12A ATP4A CD4 GAST INS
4 immune system MP:0005387 9.73 ALB ATP4A CCK CD4 CD8A CRP
5 mortality/aging MP:0010768 9.36 ALB ATP4A CD4 CD8A GAST INS

Drugs & Therapeutics for Duodenitis

Drugs for Duodenitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
6
Atorvastatin Approved Phase 4 134523-00-5 60823
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Levodopa Approved Phase 4 59-92-7 6047
9
Pantoprazole Approved Phase 4 102625-70-7 4679
10
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
11
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
13 Cromolyn Sodium Phase 4
14 Respiratory System Agents Phase 4
15 Anti-Infective Agents Phase 4
16 Antiparasitic Agents Phase 4
17 Antiprotozoal Agents Phase 4
18 Anti-Bacterial Agents Phase 4
19 Citrate Phase 4
20
Bismuth Phase 4 7440-69-9 16682734 105143
21 Antibiotics, Antitubercular Phase 4
22 diuretics Phase 4
23 Monoamine Oxidase Inhibitors Phase 4
24 Antimalarials Phase 4
25 Expectorants Phase 4
26 Anti-Infective Agents, Local Phase 4
27 Dopamine Agents Phase 4
28 Antiparkinson Agents Phase 4
29 Anti-Ulcer Agents Phase 4
30 Proton Pump Inhibitors Phase 4
31 Antacids Phase 4
32 Gastrointestinal Agents Phase 4
33 Antineoplastic Agents, Hormonal Phase 4
34
Vildagliptin Approved, Investigational Phase 2, Phase 3 274901-16-5 6918537
35
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
36
Pioglitazone Approved, Investigational Phase 2, Phase 3 111025-46-8 4829
37
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
38
Clarithromycin Approved Phase 3 81103-11-9 84029
39
Scopolamine Approved, Investigational Phase 3 51-34-3, 6533-68-2 5184
40
Ketoprofen Approved, Vet_approved Phase 3 22071-15-4 3825
41
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
42
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
43
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
44
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
45
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
46
Ketotifen Approved Phase 3 34580-13-7, 34580-14-8 3827
47
Rabeprazole Approved, Investigational Phase 3 117976-89-3 5029
48
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
49
Dexlansoprazole Approved, Investigational Phase 3 138530-94-6, 103577-45-3 9578005
50
Lansoprazole Approved, Investigational Phase 3 103577-45-3 3883

Interventional clinical trials:

(show top 50) (show all 233)
# Name Status NCT ID Phase Drugs
1 Therapeutic Effect of Ursodeoxycholic Acid on Duodenal Permeability and Meal Related Sensory Motor Function in Functional Dyspepsia Patients Unknown status NCT03004118 Phase 4 Placebo Oral Tablet;Ursochol oral tablet
2 The Role of Mast Cells on Duodenal Permeability After Duodenal Acid Perfusion in Healthy Volunteers Unknown status NCT02664051 Phase 4 Nalcrom;placebo
3 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
4 Endoscopic Treatment of Difficult Bile Duct Stones: Use of Direct Visualization System ("Spyglass Direct Visualization System") Associated With Electrohydraulic Lithotripsy (EHL) X Hydrostatic Balloon Dilation of the Major Duodenal Papilla Unknown status NCT02703077 Phase 4
5 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
6 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
7 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
8 The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study Completed NCT03342456 Phase 4 Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets
9 Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin Completed NCT00331565 Phase 4
10 Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
11 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
12 Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes Mellitus (T2DM) Completed NCT00456352 Phase 4
13 Effect of Proton Pump Inhibitors on the Duodenal Microbiome in Healthy Volunteers and Functional Dyspepsia Patients Completed NCT03545243 Phase 4 Pantoprazole 40mg
14 Duodenal Neuro-immune Interactions and Effects of PPI in Functional Dyspepsia Not yet recruiting NCT04713969 Phase 4 Pantoprazole 40mg
15 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Terminated NCT02032784 Phase 4 octreotide
16 Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
17 Efficacy and Safety of Autologous Bone Marrow Derived Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus Completed NCT01759823 Phase 2, Phase 3
18 Partially Covered Versus Uncovered Pyloro-duodenal Stents for Unresectable Malignant Gastric Outlet Obstruction. A Double Blinded Randomised Controlled Trial. Completed NCT03223831 Phase 3
19 A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer Completed NCT01452724 Phase 3 TAK-438;Placebo;Lansoprazole;Placebo
20 Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Open-label Trial- Completed NCT01398410 Phase 2, Phase 3 Rabeprazole;Rabeprazole
21 Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial- Completed NCT01397448 Phase 2, Phase 3 E3810;E3810;Teprenone
22 A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter Pylori Infection Completed NCT03050359 Phase 3 TAK-438;Lansoprazole;TAK-438 Placebo;Lansoprazole Placebo;Bismuth-Containing Quadruple Therapy
23 Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase3 Trial in China Completed NCT00952978 Phase 3 10 mg ilaprazole;20 mg omeprazole
24 Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Rabeprazole-Controlled,Multicenterand Phase3 Trial in China in China Completed NCT02847455 Phase 2, Phase 3 5 mg ilaprazole;10 mg ilaprazole;10 mg Rabeprazole
25 Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies After Stem Cell Transplantation in T2DM Completed NCT02662400 Phase 2, Phase 3
26 A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin Completed NCT01452763 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
27 A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use Completed NCT01069939 Phase 3 Esomeprazole;Placebo
28 A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID). Completed NCT01452750 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
29 Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial Completed NCT00731198 Phase 3 Drotaverine hydrochloride;Hyoscine-N-butylbromide
30 A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00595517 Phase 3 Esomeprazole 20 mg
31 A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00542789 Phase 3 Esomeprazole;Placebo
32 A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID) Completed NCT01456260 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
33 A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin Completed NCT01456247 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
34 A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated With Daily NSAID Use in Patients at Risk Completed NCT00629928 Phase 3 Esomeprazole;Esomeprazole;Placebo
35 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy Completed NCT01568398 Phase 3 TAK-438
36 Safety, Tolerability and Efficacy of FDC Ketoprofen + Omeprazole in Patients With Rheumatological Conditions With History or Who Are at Risk of Developing NSAID Associated Benign Gastric Ulcers, Duodenal Ulcers and Gastroduodenal Erosions Completed NCT00971581 Phase 3 FDC KETOPROFEN+OMEPRAZOLE
37 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy Completed NCT01568385 Phase 3 TAK-438
38 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
39 A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug Completed NCT00787254 Phase 3 Lansoprazole;Gefarnate
40 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Recruiting NCT04322604 Phase 3 lirentelimab (AK002)
41 A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma (PREACT Study) Recruiting NCT03013010 Phase 3 Tegafur-Gimeracil-Oteracil Potassium;Oxaliplatin
42 EUS - Guided Choledocho-duodenostomy Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Common Bile Duct Strictures. A Multi-centred Randomised Controlled Trial Recruiting NCT03000855 Phase 2, Phase 3
43 An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients With Reflux Esophagitis and for the Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer in Japanese Paediatric Patients Treated With Non-steroidal Anti-inflammatory Drugs or Low-dose Aspirin Recruiting NCT03553563 Phase 3 D961H capsule 10mg;D961H sachet 10mg
44 Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia Recruiting NCT02484248 Phase 3 Ketotifen;Placebo
45 A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Enrolling by invitation NCT04620811 Phase 3 lirentelimab
46 A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers. Not yet recruiting NCT04215653 Phase 3 Anaprazole Sodium;Rabeprazole;Rabeprazole Placebo;Anaprazole Sodium Placebo
47 Coxib-inhibition of Duodenal Polyp Growth in Familial Adenomatous Polyposis Terminated NCT00844727 Phase 2, Phase 3 Rofecoxib;placebo
48 A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin. Terminated NCT00762359 Phase 3 Lansoprazole;Gefarnate
49 Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3 exisulind
50 Efficacy and Safety of Exocrine Pancreatectomy With Neoprene®-Based Glue After High-risk Pancreatoduodenectomy (PD) in Patients With Pancreatic, Papilla, Duodenal, and Distal Choledochus Neoplasm Unknown status NCT03738787 Phase 2

Search NIH Clinical Center for Duodenitis

Cochrane evidence based reviews: duodenitis

Genetic Tests for Duodenitis

Anatomical Context for Duodenitis

MalaCards organs/tissues related to Duodenitis:

40
Bone Marrow, Liver, Bone, Small Intestine, Pancreas, T Cells, Heart

Publications for Duodenitis

Articles related to Duodenitis:

(show top 50) (show all 1510)
# Title Authors PMID Year
1
[Analysis of the importance of Helicobacter pylori strains in children with gastric and duodenal mucosal inflammatory changes]. 54 61
16733275 2005
2
Consensus and variable region PCR analysis of Helicobacter pylori 3' region of cagA gene in isolates from individuals with or without peptic ulcer. 61 54
11158115 2001
3
A rare case of multiple carcinoids and endocrine cell micronests in a patient with chronic duodenitis. 61 54
10964325 2000
4
Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. 61 54
9922305 1999
5
[On the pathogenesis and treatment of erosive gastritis and duodenitis]. 54 61
10380457 1999
6
[Helicobacter pylori CagA antigen antibodies]. 61 54
9748734 1998
7
Does CagA contribute to ulcer pathogenesis in a developing country, such as Sudan? 61 54
9855047 1998
8
The effects of hemodialysis on duodenal and gastric mucosal changes in uremic patients. 54 61
8738662 1996
9
Immune Checkpoint Inhibitor-Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. 61
33501492 2021
10
[Thrombocytopenia and thromboses in a young woman]. 61
33005993 2021
11
Novel Case Report: A Previously Reported, but Pathophysiologically Unexplained, Association Between Collagenous Colitis and Protein-Losing Enteropathy May Be Explained by an Undetected Link with Collagenous Duodenitis. 61
33537921 2021
12
Vitamin D deficiency causing eosinophilic esophagogastroenteritis and ascites: a rare association. 61
33541947 2021
13
13C urea breath test to identify Helicobacter pylori Infection in patients with upper gastrointestinal bleeding admitted to the Emergency Department. 61
33577035 2021
14
Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study. 61
33440255 2021
15
Urinary Excretion of Iohexol as a Permeability Marker in a Mouse Model of Intestinal Inflammation: Time Course, Performance and Welfare Considerations. 61
33406796 2021
16
Alterations in the histological features of the intestinal mucosa in malnourished adults of Bangladesh. 61
33504937 2021
17
How is the duodenal mucosa in Functional Dyspepsia? 61
33393335 2021
18
Findings of Esophagogastroduodenoscopy in Patients Suspected of Upper Gastrointestinal Bleeding Referred to the Main Endoscopy Unit at King Fahad Specialist Hospital. 61
33409096 2020
19
Analysis of gastroscopy results among healthy people undergoing a medical checkup: a retrospective study. 61
33297981 2020
20
Acute necrotising duodenitis. 61
33283621 2020
21
Asymptomatic Duodenitis and Helicobacter pylori associated Dyspepsia in 2-Year-Old Chronic Malnourished Bangladeshi Slum-Dwelling Children: A Cross-Sectional Study. 61
33099650 2020
22
Prevalence and concordant occurrence of esophageal, gastric, duodenal, and colonic eosinophilia. 61
32666091 2020
23
Comparison of endoscopic and pathological findings of the upper gastrointestinal tract in transplant candidate patients undergoing hemodialysis or peritoneal dialysis treatment: a review of literature. 61
33092560 2020
24
RISK FACTORS AND COMORBIDITY IN DIFFERENT TYPES OF FUNCTIONAL DYSPEPSIA: RETROSPECTIVE COHORT ANALYSIS. 61
33270586 2020
25
Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. 61
33085861 2020
26
Mycobacterial Airsacculitis Caused by Mycobacterium fortuitum in a Southern Rockhopper Penguin (Eudyptes chrysocome). 61
33099984 2020
27
The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system. 61
33074400 2020
28
Radiation-induced damage in the upper gastrointestinal tract: clinical presentation, diagnostic tests and treatment options. 61
33317797 2020
29
Gastrointestinal Pathologies in Patients After Successful Renal Transplantation. 61
32713818 2020
30
Geographic Disparities in Clinical Characteristics of Duodenitis-Proximal Jejunitis in Horses in the United States. 61
32972682 2020
31
Esophageal, Gastric, and Duodenal Histologic Findings in Patients with Feeding Difficulties. 61
32942680 2020
32
Long-term risk of dementia following hospitalization due to physical diseases: A multicohort study. 61
32886434 2020
33
Helicobacter pylori colonisation of duodenal foveolar metaplasia requires concurrent gastric infection. 61
32934104 2020
34
Screening Esophagogastroduodenoscopy Before Laparoscopic Sleeve Gastrectomy: Results in 819 Patients. 61
32882153 2020
35
Upper Gastrointestinal Manifestations of Inflammatory Bowel Disease. 61
32773192 2020
36
Demographic profile and endoscopic findings among patients with upper gastrointestinal bleeding in Ahmadu Bello University Teaching Hospital, Zaria, North-Western Nigeria. 61
32788496 2020
37
An Unusual Cause of Duodenitis. 61
32828815 2020
38
Immune Checkpoint Inhibitor-Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. 61
32628864 2020
39
An extremely rare case of nivolumab-associated macroscopic duodenitis with spontaneous regression. 61
32405415 2020
40
Study to evaluate the etiology of iron deficiency anemia at a teaching hospital in northeastern part of India. 61
32984176 2020
41
Immune checkpoint inhibitor-associated celiac disease. 61
32581063 2020
42
Immunosuppression-induced clonal T-cell lymphoproliferative disease causing severe diarrhoea mimicking coeliac disease following renal transplantation: a case report. 61
32522162 2020
43
Correlation between intestinal health and coccidiosis prevalence in broilers in Brazilian agroindustries. 61
31756388 2020
44
Analysis of Somatostatin-Secreting Gastric Delta Cells according to Upper Abdominal Symptoms and Helicobacter pylori Infection in Children. 61
32483545 2020
45
Iron pill-induced duodenitis: A distinct pattern of duodenal mucosal injury in a patient with a duodenal mass. 61
32146003 2020
46
Nasogastric Intubation as Health and Safety Risk in Equine Practice-A Questionnaire. 61
32303319 2020
47
Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. 61
32338534 2020
48
Duodenal tuberculosis; uncommon cause of gastric outlet obstruction. 61
31228078 2020
49
Prevalence of Upper Gastrointestinal Pathology in Patients with Obesity on Preoperative Endoscopy. 61
32612344 2020
50
Focal duodenal necrosis in chickens: attempts to reproduce the disease experimentally and diagnostic considerations. 61
31983302 2020

Variations for Duodenitis

Expression for Duodenitis

Search GEO for disease gene expression data for Duodenitis.

Pathways for Duodenitis

GO Terms for Duodenitis

Cellular components related to Duodenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 TNF S100A8 INS GAST CRP CD8A
2 endoplasmic reticulum lumen GO:0005788 9.46 TOR1A INS CD4 ALB
3 extracellular space GO:0005615 9.23 TNF S100A8 INS GAST CRP CCK

Biological processes related to Duodenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of inflammatory response GO:0050729 9.5 TNF TGM2 S100A8
2 regulation of protein secretion GO:0050708 9.46 TNF INS
3 sodium ion export across plasma membrane GO:0036376 9.43 ATP4A ATP12A
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.43 TNF S100A8 CCK
5 cellular potassium ion homeostasis GO:0030007 9.4 ATP4A ATP12A
6 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.37 ATP4A ATP12A
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.26 TNF TGM2 MALT1 CD4
8 negative regulation of lipid storage GO:0010888 9.16 TNF CRP
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 8.92 TNF S100A8 MALT1 INS

Molecular functions related to Duodenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.54 INS GAST CCK
2 protease binding GO:0002020 9.5 TNF MALT1 INS
3 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP4A ATP12A
4 identical protein binding GO:0042802 9.23 TOR1A TNF TGM2 MALT1 INS CRP
5 potassium-transporting ATPase activity GO:0008556 9.16 ATP4A ATP12A
6 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP4A ATP12A

Sources for Duodenitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....